Drug Profile

OV 329

Alternative Names: OV-329

Latest Information Update: 31 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Northwestern University
Developer Ovid Therapeutics
Class Antiepileptic drugs; Small molecules
Mechanism of Action 4-aminobutyrate transaminase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Epilepsy
Preclinical Seizures

Most Recent Events

31 Mar 2026 OV 329 is still in phase-I development for Epilepsy (In volunteers) in USA (PO)
18 Mar 2026 Ovid Therapeutics plans to initiate a proof-of-concept safety and signal-finding study of OV 329 in patients with TSC-associated Seizures in the fourth quarter of 2026
18 Mar 2026 Adverse events data from a phase I trial in Epilepsy released by Ovid Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com